<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24978">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781584</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-384-3914</org_study_id>
    <nct_id>NCT02781584</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of Selonsertib, GS-0976, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of
      selonsertib (GS-4997), GS-0976, and GS-9674 in adults with nonalcoholic steatohepatitis
      (NASH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2016</start_date>
  <completion_date type="Anticipated">October 20, 2017</completion_date>
  <primary_completion_date type="Anticipated">September 22, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 12 weeks plus 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Serious Adverse Events</measure>
    <time_frame>Up to 12 weeks plus 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Laboratory Abnormalities</measure>
    <time_frame>Up to 12 weeks plus 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>Selonsertib (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selonsertib (1 x 18 mg) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-0976 (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-0976 (2 x 10 mg) for 12 weeks
Enrollment into Cohort 2 will begin upon completion of enrollment for Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9674 (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9674 (3 x 10 mg) for 12 weeks
Enrollment into Cohort 3 will begin upon completion of enrollment for Cohort 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selonsertib + GS-9674 (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selonsertib (1 x 18 mg) + GS-9674 (1 x 30 mg) for 12 weeks
Enrollment into Cohort 4 will begin upon completion of enrollment for Cohort 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selonsertib</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>Selonsertib (Cohort 1)</arm_group_label>
    <arm_group_label>Selonsertib + GS-9674 (Cohort 4)</arm_group_label>
    <other_name>GS-4997</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-0976</intervention_name>
    <description>Capsules administered orally once daily</description>
    <arm_group_label>GS-0976 (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9674</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>GS-9674 (Cohort 3)</arm_group_label>
    <arm_group_label>Selonsertib + GS-9674 (Cohort 4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Males and females between 18-75 years of age; inclusive based on the date of the
             screening visit

          -  Willing and able to provide informed consent prior to any study specific procedures
             being performed

          -  Meets the following conditions:

               -  Clinical diagnosis of non-alcoholic fatty liver disease, screening FibroTest® &lt;
                  0.75, unless a historical liver biopsy within 12 months of screening does not
                  reveal cirrhosis, screening magnetic resonance imaging - proton density fat
                  fraction (MRI-PDFF) with ≥ 10% steatosis, and screening magnetic resonance
                  elastography (MRE) with liver stiffness ≥ 2.88 kPa OR

               -  A historical liver biopsy within 12 months of screening consistent with NASH
                  (defined as the presence of steatosis, inflammation, and ballooning) with stage
                  2-3 fibrosis according to the NASH Clinical Research Network (CRN)
                  classification (or equivalent) and no documented weight loss &gt; 5% between the
                  date of the liver biopsy and screening

        Key Exclusion Criteria:

          -  Pregnant or lactating females

          -  Other causes of liver disease including autoimmune, viral, and alcoholic liver
             disease

          -  Cirrhosis of the liver

          -  Any history of decompensated liver disease, including ascites, hepatic encephalopathy
             or variceal bleeding

          -  History of liver transplantation

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>384-3914alerts@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>May 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
